Compare IDEXX Laboratories, Inc. (IDXX) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Jones Lang LaSalle Inc — how do they compare? IDEXX Laboratories, Inc. trades at $554.89 (market cap $44.48B), while Jones Lang LaSalle Inc trades at $326.44 (market cap $15.12B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.9× Jones Lang LaSalle Inc's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | JLL | |
|---|---|---|
Market Cap | $44.48B | $15.12B |
Sector | Health | Real Estate |
52-Week High | $766.68 | $358.66 |
52-Week Low | $520.87 | $253.48 |
Enterprise Value | $45.38B | $18.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
JLL trades at $325.94, down 1.43% today, but maintains a bullish technical outlook with strong moving average signals. The company shows solid fundamental improvement with revenue growing from $20.9B in 2022 to $26.1B in 2025, while net income margin expanded to 3.35%. Recent earnings beats and positive analyst coverage (54.55% buy rating) support the stock's upward trajectory, with a consensus price target of $405.50 representing 24.4% upside potential.
JLL presents a compelling investment case with improving profitability, strong cash flow generation ($1.19B operating cash flow in 2025), and positive business momentum in commercial real estate services. Key risks include exposure to commercial real estate cycles and potential economic slowdowns, but the company's debt-to-asset ratio improvement to 9.32% and consistent earnings beats provide fundamental support for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
